Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781585 | 0.82 | ALDH1A1 (0.33) | FAAH | |
| SCHEMBL12567246 | 0.82 | ALDH1A1 (0.39) | FAAH | |
| SCHEMBL13415700 | 0.82 | ALDH1A1 (0.39) | FAAH | |
| SCHEMBL2369153 | 0.80 | FAAH (0.43) | FAAH | |
| SCHEMBL7360452 | 0.80 | FAAH (0.32) | FAAH | |
| SCHEMBL24759068 | 0.78 | FAAH (0.35) | FAAH | |
| SCHEMBL16689921 | 0.78 | FAAH (0.35) | FAAH | |
| SCHEMBL14671182 | 0.78 | ALDH1A1 (0.41) | ELANE | |
| SCHEMBL753366 | 0.78 | — | — | |
| SCHEMBL18762469 | 0.77 | MLYCD (0.34) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532987-B2 | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases | GENENTECH, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150111869-A1 | USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | GENENTECH, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111869-A1 | USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | GENENTECH, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015032840-A1 | COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR USE IN TREATMENT OF HYPERPROLIFERATIVE DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111869-A1 | USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | MAPK13, MAPK3, MAPK1 | FAAH 4355/4885ELANE 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.